ezetimibe / Generic mfg. - LARVOL DELTA

Statin-Ezetimibe Attenuates Hepatic Inflammation and Fibrosis in a Diet- and Toxin-Induced Steatohepatitis Model, Associated with Macrophage NF-κB Inhibition. (PubMed, Cells) - "Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of adults globally; its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), has limited pharmacological options beyond the recently approved resmetirom...Simvastatin (5 mg/kg) and/or Ezetimibe (10 mg/kg) were added to the diet for 4 weeks... Statin-Ezetimibe combination exerts anti-inflammatory and anti-fibrotic effects in a multi-hit murine model of MASH with advanced fibrosis associated with macrophage NF-κB inhibition in vitro and with reduced hepatic inflammatory signaling in vivo. These findings provide mechanistic rationale for the hepatic benefits of this widely used regimen in MASH patients with dyslipidemia, supporting its evaluation as a drug-repurposing strategy."

Journal • Dyslipidemia • Fibrosis • Hepatology • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • IL1B • IL6 • TGFB1 • TNFA

EZE-TRACK: LDL Cholesterol Reduction Following Ezetimibe Initiation (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Universidade do Porto

New P4 trial • Atherosclerosis • Cardiovascular • Dyslipidemia • APOB

Evolocumab for high cardiovascular risk patients without previous stroke: a network meta-analysis of randomized controlled trials (ESC 2026) - "Purpose: To investigate the efficacy and safety of non-statin treatments—including evolocumab, alirocumab, enlicitide, inclisiran, evinacumab, omega-3 fatty acids, and ezetimibe—in high CV risk patients without previous stroke. Evolocumab had the potential to be the first-line non-statin option for high CV risk patients without previous stroke due to its efficacy in reducing MACE, CV mortality, LDL-C, and Lp(a)."

Retrospective data • Cardiovascular • Dyslipidemia • Myocardial Infarction

Contemporary non-statin therapies for dyslipidemia management: achieving current lipid targets. (PubMed, Front Med (Lausanne)) - "Third evidence indicates that non-statin therapies-including ezetimibe, bempedoic acid, PCSK9 inhibitors (evolocumab and alirocumab), and inclisiran-provide substantial LDL-C reductions and reduce cardiovascular events...Additionally, the fixed-dose combination of bempedoic acid and ezetimibe produces an approximately 36.2% reduction in LDL-C in high-risk patients...Furthermore, inflammation (measured by hsCRP) provides complementary prognostic information beyond LDL-C. This expert position paper proposes practical algorithms for a precision medicine approach in Latin America, matching treatment intensity to individual risk profiles for the primary and secondary prevention of atherosclerotic cardiovascular disease."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Inflammation • Metabolic Disorders • CRP

Alirocumab and cardiovascular outcomes in patients without a prior ischemic event (ESC 2026) - "VESALIUS-CV recently showed that evolocumab lowers cardiovascular event rates in patients without prior myocardial infarction (MI) or stroke...Use of lipid-lowering therapy, including statin+ ezetimibe combination, was high in both groups (Table)... In this population-based cohort of patients with ASCVD without prior acute ischemic events, alirocumab was associated with lower 4-year risk of all-cause death, MI, or ischemic stroke, supporting the clinical value of alirocumab in these patients and complementing recent randomized trial evidence."

Clinical • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Ischemic stroke • Myocardial Infarction

Efficacy of PCSK9 inhibitors in patients with peripheral artery disease: insights from the AT-TARGET-IT Registry (ESC 2026) - "LDL-cholesterol (LDL-C) lowering improves outcomes in PAD, and randomized evidence supports the use of proprotein convertase subtilisin/kexin type-9 inhibitors (PCSK9i) on top of statin ± ezetimibe therapy...The purpose of this subanalysis was to investigate efficacy and safety of PCSK9i in patients with PAD. Patients with PAD initiating evolocumab or alirocumab (75, 150 or 300 mg), according to ESC/EAS Guidelines indications and national reimbursement criteria, were enrolled in the AT-TARGET-IT registry... A total of 124 patients with PAD were enrolled in the AT-TARGET-IT registry (61.3% male, median age 59 years), of whom 118 had at least one follow-up recorded. Of these patients, 61.3% had hypertension, 17.7% had type 2 diabetes mellitus, and 21.8% had a previous history of lower limb revascularization. Baseline median ankle brachial index (ABI) was 0.8 (IQR 0.7-0.9), and most patients had symptomatic PAD, predominantly Fontaine stage IIa (30.6%) and IIb (48.4%),..."

Clinical • Cardiovascular • Hypertension • Peripheral Arterial Disease

The LUNAR-HF Trial: a randomised comparison of inclisiran versus evolocumab in ischaemic heart failure with reduced ejection fraction (ESC 2026) - "In patients with ischaemic HFrEF on maximal statin/ezetimibe therapy, Inclisiran was significantly more effective than Evolocumab in achieving the stringent LDL-C target of <55 mg/dL at 5 months, with a favourable safety profile and less frequent dosing. These findings support Inclisiran as a potent and convenient lipid-lowering strategy in this high-risk cohort"

Clinical • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure

Management of Lorlatinib-Induced Hyperlipidemia With PCSK9 Inhibitors: A Case Series (IASLC-WCLC 2026) - "Case Description : Case 1: A 66-year-old male on second-line lorlatinib 75 mg daily had normal baseline lipid levels but progressed to mixed hyperlipidemia refractory to pravastatin 40 mg daily, and partially improved on rosuvastatin 40 mg daily and ezetimibe 10 mg daily. After prolonged lifestyle modification attempts over four and a half years, alirocumab 75 mg/mL every 2 weeks (Q2W) was added, achieving lipid control (Figure 1)...She transitioned to evolocumab 140 mg/mL Q2W with bempedoic acid 180 mg daily with mild improvement...Conclusions : These four case reports illustrate the benefit of addition of a PSCK9i in treatment-related, refractory hyperlipidemia. PSCK9i are effective in lowering total cholesterol and LDL in patients with lorlatinib-induced hyperlipidemia and may be considered early in severe and statin-refractory cases."

Clinical • Dyslipidemia • Hypertension • Immunology • Lung Cancer • Mixed Hyperlipidemia • Musculoskeletal Pain • Non Small Cell Lung Cancer • Solid Tumor • ALK

Cholesterol Metabolism in Cancer Patients: Mechanisms, Treatment-Related Effects, and Cardio-Oncology Management. (PubMed, Oncol Res) - "Novel agents, including ezetimibe, bempedoic acid, and proprotein convertase subtilisin-kexin type 9 inhibitors, provide additional therapeutic options, with emerging evidence supporting their immunomodulatory and anticancer properties, especially in combination with immune checkpoint inhibitors. In addition, several anticancer therapies may profoundly affect lipid metabolism, thereby contributing to CV risk in cancer patients. The aim of this review is to provide a comprehensive overview of the interplay between cholesterol metabolism and cancer, to summarize the lipid-modifying effects of anticancer therapies, and to discuss the potential role of lipid-lowering strategies within the evolving framework of cardio-oncology care."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders • Oncology

Signal Detection of Adverse Events Associated with PCSK9 Inhibitors: A Nationwide Sequence Symmetry and Combined Worldwide Disproportionality Analysis. (PubMed, Drug Saf) - "This study, combining analyses from large medico-administrative and spontaneous reports databases, identified only two potential signals relating to PCSK9i. Both appeared to be linked to residual indication bias or confounding factors."

Adverse events • Journal

Ezetimibe/bempedoic acid combination in statin-induced anti-HMGCR positive immune-mediated necrotizing myopathy: a case series. (PubMed, Rheumatology (Oxford)) - "EZ/BA combination therapy appears safe and effective in patients with statin-induced IMNM. However, confirmation through longer follow-up and validation in multicenter cohorts is required before recommendation as a viable alternative to statins is appropriate."

Journal • Dyslipidemia • Immunology • Metabolic Disorders • Myositis

Contemporary lipid management and achievement of LDL-C targets after acute myocardial infarction in Japan: Insights from the K-ACTIVE registry. (PubMed, J Cardiol) - "Although approximately 60% of patients achieved the current LDL-C target, this proportion may be insufficient in light of the anticipated transition toward a lower LDL-C threshold (<55 mg/dL) proposed in recent Japanese scientific statements and aligned with contemporary international guidelines. Early intensification of lipid-lowering therapy, including high-intensity statins and ezetimibe, may be warranted in selected patients to optimize secondary prevention."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Metabolic Disorders • Myocardial Infarction

Discovering repurposable drugs for Alzheimer's disease and related dementias: target trial emulation using decentralised real-world data. (PubMed, EBioMedicine) - "20 widely used medications may be associated with reduced progression from MCI to ADRD and represent promising candidates for clinical evaluation as repurposed therapies for dementia."

Journal • Real-world evidence • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Dementia • Pain

Effects of different statin-based lipid-lowering therapies on stabilization and regression of carotid plaque: a randomized open-label trial. (PubMed, Front Pharmacol) - P=N/A | "In this randomized open-label trial, participants were randomly assigned to one of four treatment groups: atorvastatin 20 mg/day (Statin), atorvastatin 10 mg/day + ezetimibe 10 mg/day (Statin_E), atorvastatin 10 mg/day + alirocumab 75 mg every 2 weeks (Statin_P), and atorvastatin 10 mg/day + ezetimibe 10 mg/day + alirocumab 75 mg every 2 weeks (Statin_EP). The trial was registered in the Chinese Clinical Trial Registry (No. ChiCTR2200058389) on 2022-04-08."

Journal • Atherosclerosis • Cardiovascular

Real-world use of bempedoic acid for hypercholesterolaemia: a German multicentre, retrospective, cohort study. (PubMed, Lipids Health Dis) - "Findings from this real-world, multicentre study conducted in Germany show that bempedoic acid may present an effective treatment option for patients with hypercholesterolaemia who are already receiving LLT, in addition to being an effective option for patients not receiving/tolerating other LLTs. The magnitude of LDL-C reduction differed across background treatment strategies, while suspected adverse events and treatment discontinuation were common in this specialist-care cohort."

Journal • Observational data • Real-world evidence • Retrospective data • Cardiovascular • Dyslipidemia • Mixed Hyperlipidemia • Musculoskeletal Pain • Pain

Familial Hypercholesterolemia. (PubMed, Methodist Debakey Cardiovasc J) - "Prompt recognition and treatment with statins, often combined with ezetimibe, modifies the natural course of the disease...In statin-intolerant patients, bempedoic acid may provide additional therapeutic options. The most severe form, homozygous FH (HoFH), has an estimated prevalence of ~1 in 367,000 individuals and is associated with ASCVD in youth, calcific aortic stenosis, and a markedly reduced life expectancy. Patients with HoFH require specialized care and may need LDL apheresis and specific orphan drugs such as lomitapide or evinacumab."

Biomarker • Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Heterozygous Familial Hypercholesterolemia • Homozygous Familial Hypercholesterolemia • Metabolic Disorders • APOB

Rationale and Design of the Canadian Lipoprotein(a) Registry. (PubMed, CJC Open) - "At the time of registry entry, 104 (81.9%) patients were receiving lipid-lowering therapies, including statins (74.8%), ezetimibe (48.0%), and proprotein convertase subtilisin/kexin type 9 inhibitors (27.6%), whereas 18.1% were not taking prescription lipid-lowering therapy...The Canadian Lp(a) Registry is an ongoing prospective, observational study designed to evaluate the clinical management, cardiovascular risk profile, and outcomes for patients with elevated Lp(a). It is expected to improve our understanding of how elevated Lp(a) is managed in contemporary clinical practice and to identify opportunities to improve care."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia

Association Between Treatment of Pro-Inflammatory Conditions and Vestibular Schwannoma Risk (AAO-HNSF 2026) - "DM2 treatments included metformin, insulin, DPP-4 and SGLT2 inhibitors, sulfonylureas; dyslipidemia treatment included statins, fibrates, ezetimibe, niacin; and RA treatment included DMARDs, NSAIDs, and corticosteroids. Treatment of DM2 did not significantly impact VS risk. Surprisingly, treatment for dyslipidemia and RA was associated with increased risk, potentially due to confounding by severity, treatment selection, or surveillance bias. These findings warrant further investigation."

Brain Cancer • Diabetes • Dyslipidemia • Immunology • Inflammatory Arthritis • Metabolic Disorders • Rheumatoid Arthritis • Solid Tumor • Type 2 Diabetes Mellitus

Real-world patterns in lipid profile testing and lipid-lowering therapy in hospitalized patients: The Jurasz Lipid Study. (PubMed, Int J Cardiol Cardiovasc Risk Prev) - "Statin monotherapy remained the standard of care, with atorvastatin and rosuvastatin being the most frequently used agents. Statin monotherapy remained the cornerstone of LLT. Statin with ezetimibe was the most common therapeutic combination."

Journal • Real-world evidence • Atherosclerosis • Cardiovascular • Pediatrics

EARLY-BIRD ACS: Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome (clinicaltrials.gov) - P4 | N=400 | Recruiting | Sponsor: Taipei Medical University Hospital

New P4 trial • Acute Coronary Syndrome • Cardiovascular • Dyslipidemia • Metabolic Disorders

Secondary prevention lipid management after ACS at a DGH: a quality improvement project. (PubMed, Br J Cardiol) - "Many patients fail to achieve therapeutic lipid lowering. Strategies to address this are urgently required."

Journal • Acute Coronary Syndrome • Cardiovascular

Chitosan-TPP modification of SNEDDS enhances mucin interaction, apparent epithelial transport, and oral exposure of ezetimibe. (PubMed, Drug Deliv Transl Res) - "These findings indicate that chitosan-TPP modification of ezetimibe-loaded SNEDDS introduced mucin-interactive cationic properties and was associated with an additional improvement in apparent epithelial transport and systemic exposure beyond that achieved by SNEDDS alone. This lipid-polymer interfacial modification strategy may provide a useful formulation approach for improving the oral delivery of poorly water-soluble drugs."

Journal

Real world patterns of dyslipidemia care before and after a national fee revision in Japan: A nationwide study using a 30 million patient claims database. (PubMed, PLoS One) - "Low-density lipoprotein cholesterol goals were attained at 58.3% of outpatient visits under the previous fee and 58.5% under the new fee, and less often in secondary than in primary prevention, despite high statin use and frequent combination therapy with ezetimibe or fibrate...Cardiovascular event rates were also similar, but post-revision patient-years were limited to approximately 6 months (58,500 vs. 1,542,800 patient-years); therefore, this comparison is exploratory and cannot exclude an effect of the new fee structure. Longer follow-up and complementary designs are needed to evaluate the causal impact of the new fee on outcomes."

Journal • Real-world evidence • Retrospective data • Cardiovascular • Dyslipidemia • Metabolic Disorders

Hematologic manifestations of sitosterolemia: Phenotypic spectrum and long-term outcomes in seven genetically confirmed patients. (PubMed, Blood Cells Mol Dis) - "Sitosterolemia is an underrecognized but treatable cause of hemolytic anemia with macrothrombocytopenia. Careful peripheral smear examination demonstrating stomatocytes and giant platelets can provide an important diagnostic clue. Early recognition and targeted therapy can significantly improve clinical outcomes."

Journal • Atherosclerosis • Cardiovascular • Dyslipidemia • Hematological Disorders • Metabolic Disorders • Thrombocytopenia

Statin treatment strategy and LDL cholesterol response associate with circulating Amyloid beta 1-40 in a prospective dyslipidemia cohort. (PubMed, Thromb Haemost) - "In high-risk patients, statin initiation or intensification is associated with a short-term increase, followed by a long-term return to initial Aβ40 circulating levels, whereas patients achieving LDL-C reduction show long-term stabilization of Aβ40 levels. Further research is warranted to clarify the mechanistic insights of these observations."

Journal • Atherosclerosis • Cardiovascular • Congestive Heart Failure • Diabetes • Dyslipidemia • Heart Failure • Metabolic Disorders